NCT00492765View on ClinicalTrials.gov

Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis

PHASE4CompletedINTERVENTIONAL
Enrollment

380

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
Multiple Sclerosis
Interventions
DRUG

Interferon-beta-1a

dosage and frequency as per label

DRUG

Simvastatin

dosage and frequency as per Biogen Idec protocol

DRUG

Placebo

dosage and frequency the same as simvastatin as per Biogen Idec Protocol

Trial Locations (1)

Unknown

Coordinating Research Site, Copenhagen

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY

NCT00492765 - Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis | Biotech Hunter | Biotech Hunter